Heparins Outperform DOACs and FXII/FXI Inhibitors in Preventing Thrombin Generation: JTH Study
Journal of Thrombosis and Haemostasis (JTH) shared an insightful post on LinkedIn:
“Effect of heparins, direct oral anticoagulants, and factor XII/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study
This in vitro catheter-initiated thrombin generation model compared heparins, DOACs, and emerging FXII/FXI inhibitors. Heparins were the most effective, with UFH completely suppressing thrombin generation at clinically relevant concentrations. DOACs and fondaparinux showed limited efficacy, while FXII/FXI inhibitors (asundexian, milvexian, garadacimab, abelacimab) did not adequately prevent coagulation on artificial surfaces. Results align with clinical observations, reinforcing UFH as the gold standard in invasive endovascular procedures.”
Read the full article here:
Article: Effect of heparins, direct oral anticoagulants, and factor XII/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study
Authors: Michael Hardy, Henri Thonon, Jonathan Douxfils, Julie Vassart, Isabelle Gouin–Thibault, Sarah Lessire, Thomas Lecompte, Francois
Stay updated with Hemostasis Today.
-
Nov 15, 2025, 12:24Thomas Reiser: Can AI Keep Up with Thrombosis Specialists?
-
Nov 15, 2025, 12:13Michael Makris on Immediate Suspension of Use of Plasma Derived FIX Concentrates in Punjab
-
Nov 15, 2025, 09:32Tushar Pandey: Hounoured to Be Part of Hematocon 2025
-
Nov 15, 2025, 09:11Lisa Murphy invites You to Join Her at Stroke Foundation’s Run4Stroke Marathon
-
Nov 15, 2025, 08:56Ahmed Bennis on Potential Use of P2Y12 Inhibitors as Safer Alternative in Monotherapy
-
Nov 15, 2025, 08:39Marika Nöjd: Donating Blood is An Easy Way to Do Good!
-
Nov 15, 2025, 08:19Joseph Caprini Released His UIP 2025 Session on VTE Recurrence Risk
-
Nov 15, 2025, 07:14Paul Bolaji Invites You to ”Thrombolytic Therapy in Acute Stroke in African Patients” Seminar
-
Nov 15, 2025, 07:03Carla Goulart Peron Explores The Role of Technology and Collaboration in Global Stroke Action
